Asthma is a complex syndrome with many clinical phenotypes in children and adults. Despite the rapidly increasing prevalence, clinical investigation and epidemiological studies of asthma, the successful introduction of new drugs has been limited due to the different disease phenotypes and ethical issues. Mouse models of asthma replicate many of the features of human asthma, including airway hyperreactivity, and airway inflammation. Therefore, examination of disease mechanisms in mice has been used to elucidate asthma pathology and to identify and evaluate new therapeutic agents. In this article, we discuss the various animal models of asthma with a focus on mouse strains, allergens, protocols, and outcome measurements.

Key Words: animal model; asthma; mouse

INTRODUCTION

The prevalence of allergic airway disease is rapidly increasing world-wide in all age groups; in recent decades, the prevalence in children is reportedly over 30% in many countries and greater than 10% in some adult populations. Although understanding of the pathogenesis of the disease has progressed enormously in the last several decades, the development and addition of new therapeutic agents in asthma has been very limited. The mainstay of therapy remains inhaled corticosteroids, which although impacting the disease in significant ways, does not address all issues and in all patients.

Asthma is a complex syndrome with many clinical phenotypes. Common to all is chronic inflammation with reversible airway obstruction and airway hyperresponsiveness (AHR). The most prevalent form of asthma is atopic asthma which is initiated by the exposure to (inhaled) allergens and resultant allergen-specific immune responses. Indeed, early sensitization to allergen, by 3 yr of age, may be an important predictor for persistent wheezing 10 yr later. As we are all exposed to the same inhaled allergens, the genetic regulation of these responses is an important component in defining susceptible individuals. In addition to allergen exposure, other exposure risk factors such as viral infection, occupational exposure, air pollution, and environmental tobacco smoke are important contributors to the different phenotypes of asthma and asthma heterogeneity. Similar to other diseases, clinical investigation and epidemiological studies are essential for the advancement of knowledge and disease management. However, the ability to comprehensively assess the different disease phenotypes and inherent ethical issues are limiting factors in conducting many of the required clinical studies. As a result, animal models have been developed to study the pathogenesis of the disease, including genetic factors, to define the pathogenetic pathways and suggest new therapeutic approaches. That being said, it is clear that the results in animal studies are not easily translated to humans and therapeutic initiatives successful in animals have generally been of limited success in the clinic. This has prompted debate about the utility of animal models.

ANIMALS

Animal models of asthma have been extensively used to examine mechanisms of disease, the activity of a variety of genes and cellular pathways, and to predict the safety of new drugs or chemicals before being used in clinical studies. Advances in the understanding of the pathophysiology of asthma as an allergic airway disease would not have been possible without these models. Although asthma was associated with airway eosinophilia for more than a century, the contributors to this characteristic cellular inflammatory response followed on the descriptions of T helper cell functional heterogeneity and the
distinct cytokine profiles described initially in mice. Indeed, most of the mechanisms of disease that are discussed today derive from the studies conducted in animal models.

There is a wide variety of animal models of asthma in different species. Mice, rats, guinea pigs, ferrets, dogs, sheep, monkeys and horses have been employed to study the inflammatory processes and alterations in airway function. Each animal possesses certain advantages and disadvantages as a model of allergic airway disease (Table 1).

Mouse models of allergic airway disease offer numerous advantages when compared to the use of other animals. IgE is the primary anaphylactic antibody in mice, making this species appropriate for investigation of the role of humoral immune factors in the development of allergic airway disease. Further, mouse models offer the opportunity to explore detailed mechanisms of allergic reactions because of the availability of numerous immunological reagents such as antibodies against cytokines, growth factors, and cell surface markers. Numerous well-characterized inbred strains of mice are available, which allow direct transfer of cells between the same strain of animals for the assessment of function of specific factors and cells. In addition, the emerging technologies involving gene manipulation in animals is well-advanced in mice. The ease of breeding and short gestational period is an additional advantage. Accordingly, major advances in the understanding of the disease concept, “asthma as Th2-dominant disease”, emerged from studies in mice.

On the other hand, because of considerable physiologic differences between mice and humans, extrapolation of findings to humans needs to be judicious. To a large extent these differences explain many of the failures to translate findings in the mouse to the clinic. Among these differences is the anatomy and differentiation and branching of the airways, the vasculature, and the somewhat limited airway musculature. Mice do not exhibit spontaneous AHR and smooth muscle hyperplasia is not easily demonstrated. The mice fail to develop airway constrictive responses to histamine and for studies of neurogenic inflammation, it is difficult to detect non-adrenergic/non-cholinergic (NANC) activated or inhibitory responses. A major limiting factor in mice and in virtually all animal models is the absence of a truly chronic model, a model where challenges are experienced over many months to years, akin to the human asthmatic.

Although a majority of studies of allergic airway disease are now carried out in the mouse, the guinea pig initially was utilized as an animal model of pulmonary hypersensitivity and AHR for many decades. The guinea pig demonstrated airway constrictive responses, hyperreactivity towards cholinergic agonists, and production of hypersensitivity antibodies, including IgG1 and IgE. The major benefit of the guinea pig was the ability to target the lung as the primary target organ of a hypersensitivity response. Further, both immediate- and late-phase airway responses following allergen challenge readily developed in this species, allowing mechanistic investigation of the distinct phases of altered airway function, as well as determining the interplay between the early- and late-phase responses. The associated pulmonary inflammatory response is consistent with asthma, composed of both eosinophils and neutrophils. The guinea pig model identified the importance of airway inflammation in the development of altered airway function.

However, there are several disadvantages in using guinea pigs as a model of asthma. The shortage of inbred strains prevents

Table 1. Advantages and disadvantages of individual animal models of asthma

| Animal   | Advantage                                                                 | Disadvantage                                                                 |
|----------|---------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Mouse    | IgE is the primary anaphylactic antibody                                   | Do not exhibit spontaneous airway hyperresponsiveness                       |
|          | Numerous immunological reagents                                           | Limited airway musculature                                                   |
|          | Numerous inbred strains                                                   | Lung anatomical differences                                                  |
|          | Easy breeding                                                             | Do not respond to histamine                                                 |
|          | Short gestational period                                                  | Absence of a chronic model                                                  |
|          | Small and relatively inexpensive                                          |                                                                              |
| Rat      | IgE is the primary anaphylactic antibody                                   | Requires injection of the allergen for sensitization                       |
|          | Produce long-lasting airway response                                      | Requires adjuvants for sensitization                                          |
|          | Show immediate and late phase airway responses                            | Species-specific immunological reagents are not abundant                    |
| Guinea pig | Lung is the primary target of anaphylaxis                                | IgG1 is the major anaphylactic antibody                                      |
|          | Response to cholinergic agonists                                          | Shortage of inbred strains                                                  |
|          | Show immediate and late phase airway responses                            | Few species-specific reagents                                                |
|          | Pulmonary inflammation composed of eosinophils and neutrophils           |                                                                              |
| Rabbit   | Show immediate and late phase airway responses                            | Neonatal immunization required for late phase airway response               |
|          | Lung is the primary target of anaphylaxis                                 |                                                                              |
|          | IgE is the primary anaphylactic antibody                                   |                                                                              |
| Large animals | Horses naturally develop respiratory disorders when exposed to barn dust | Hard to handle                                                              |
|          | Monkeys develop natural sensitivity to Ascaris                            | Expensive                                                                   |

http://e-aair.org
meaningful investigation of the genetic influences on susceptibility to sensitization and development of allergic airway disease. In addition, few species-specific reagents exist, making it difficult to identify and isolate particular cell types. Another major disadvantage to the guinea pig is the predominance of IgG1 rather than IgE as the major anaphylactic antibody.21

The rat, another small rodent, has been used by numerous investigators. The production of IgE as the major anaphylactic antibody enables the study of the control of the synthesis of allergen-specific antibodies, as well as the role of this antibody in the physiological and cellular responses to allergen. Another benefit is the ability to produce long-lasting airway hyperreactivity. Both immediate- and late-phase airway responses following allergen challenge have been produced in strains of rats, however, sensitization typically requires injection of the allergen, rather than administration via the inhalation route as is used with guinea pigs.22,23 In addition, allergic sensitization, as in the mouse, requires use of adjuvants, specifically alum or Bordetella pertussis.24 Species-specific immunological reagents are not as abundant as they are in mice. These are major limitations for the study of allergic airway responses.

The rabbit provides an animal model which resembles humans in that the lung is the target organ for anaphylactic responses. This species can demonstrate both immediate- and late-phase airway responses, has vigorous NANC responses and IgE is the primary anaphylactic antibody.

Larger animals such as monkeys, sheep, and horses have been used in asthma models. However, they are hard to handle and too expensive to use on a regular basis. Horses are the only animals which naturally develop respiratory disorders characterized by acute airway obstruction when exposed to barn dust.25 Monkeys may develop natural airway sensitivity to Ascaris.26

In light of the predominant use of mice as surrogates, this review article focuses on mouse models. In considering the use of mice, several distinct components need to be considered, the genetic background of the mice, the allergen, the experimental approach, and the outcome measures. The interplay between these four components is exceptionally complex and understanding the biological implications is essential to the extrapolation to human disease.

**STRAINS OF MICE**

The availability of various inbred mouse strains is an advantage, but problems can arise if an inappropriate mouse strain is selected. The ability to induce parameters of allergic airway inflammation and AHR varies greatly among the different strains with both responders and non-responders. A/J and AKR/J mice display high levels of allergen-induced AHR and reactivity to methacholine.27 In contrast, C3H/HeJ and DBA/2 mice are comparatively resistant to the development of allergen-induced AHR.27,28 Among the strains, BALB/c and C57BL/6 mice are the most widely used due to their well-characterized immunological responses. BALB/c mice typically mount Th2-dominated immune responses, and the induction of parameters of allergic responses such as allergen-specific IgE, AHR, and eosinophilic airway inflammation are robust. Conversely, C57BL/6 mice exhibit Th1-dominated immune responses, and have limitations in the development of allergic airway responses compared with BALB/c mice especially in the development of allergen-specific IgE responses and airway responsiveness to inhaled methacholine. Surprisingly, in response to allergen challenge, for example to ovalbumin (OVA), they do develop a robust BAL eosinophilic response,29 and in the tissue tend to accumulate more eosinophils in the parenchyma than around the airways, in contrast to BALB/c mice where eosinophils accumulate around the airways.30 However, C57BL/6 mice are widely used as strains of most gene-manipulated mice are on this background.

The availability of genetically-manipulated animals enables the investigation of the genetic influence on susceptibility to sensitization and development of allergic airway inflammation. Targeting of specific genes has served to identify pathways uniquely involved in disease development and progression. Thus, the contribution of a given molecule in disease development has been identified through the use of gene-deletion or

| Methods | Advantage | Disadvantage |
|---------|-----------|--------------|
| Non-invasive | Fast and easy | Interference from upper airways |
| | Use aerosolized stimulants | Prone to artifacts (movement) |
| | Repeated and long term measurements in the same animal | Breathing patterns only but not physiological values |
| | Normal breathing pattern with no need for anesthesia or tracheal instrumentation | No direct assessment of pulmonary mechanics |
| Invasive | Reproducible and precise | Need for tracheostomy |
| | Avoid changes in the upper airways | Need for anesthesia |
| | Opportunity for bronchoalveolar lavage fluid collection | Need for mechanical ventilation |
| | Based on physiological principles | No repeated measurements |
| | Intact anatomical relationship in the lung | Expertise |
knockout mice, which are genetically-manipulated to produce a defective or non-functional version of a gene-related product or to overexpress a gene product. However, such studies require careful scrutiny as the effects are developmental in origin, and genetic manipulation circumvents naturally occurring regulatory or control mechanisms or may be compensated by unknown pathways. To circumvent some of these limitations, technologies using conditional knockout approaches have been developed in which the developmental concerns are bypassed and where the target gene can be directly manipulated at defined times. Transgenic mice have also been used to examine the impact of overexpression of a gene of interest on the course of disease development. The transgenic genes can disrupt the expression of other genes which can be induced by the random insertion of target genes. Therefore, once animals expressing the transgene have been made, it is important to confirm that insertion did not disrupt the expression of other genes.

ALLEGENS

A number of allergens have been used in animal models of asthma. In most studies, OVA has been used to sensitize and challenge host animals. OVA is relatively inexpensive, can be highly purified, the immunodominant epitopes have been well-characterized, and recombinant peptides have been generated. Purified OVA can be prepared without protease or endotoxin which is abundant in other allergens.31 In most strains, repeated inhalation of OVA may induce the development of tolerance, rather than sustained allergic airway responses. For sensitization, OVA is usually combined with adjuvant and injected to prime for allergic airway inflammation.42 Following sensitization, a series of inhaled or intranasal challenges are administered to elicit responses. OVA-induced allergic airway models may not represent the same conditions experienced by asthmatics where allergen exposure may be more frequent and for much longer periods of time. Although allergens represent an important component of allergy induction, other factors such as lipopolysaccharides (LPS, endotoxin) may contribute as they are ubiquitous in the environment. Small amounts of LPS usually contaminate preparations of OVA and are likely essential for sensitization in mice. In one study sensitization to OVA via the intranasal route was shown to be dependent on LPS in the preparation but this requirement was bypassed when sensitization systemically was combined with adjuvant.43 LPS-free OVA may induce tolerance and prevent development of allergic airway inflammation or AHR.43 Extracts or purified proteins derived from potent human allergens including house dust mite (HDM), cockroach, ragweed, or fungi have been increasingly used as allergens in mice and other species.45-41 Repeated administration of a combination of three allergens may avoid the development of tolerance.42 These allergens induce asthma attacks in humans and some studies have demonstrated their potency to induce chronic airway inflammation and tissue remodeling in mice. It is also apparent that even following the same protocols, different allergens in different strains elicit quite different responses.43

EXPERIMENTAL PROTOCOLS

At the present time there is no standardized experimental protocol; most laboratories have developed their own protocols either with major or minor modifications. Simple reliance on a single model poses many problems when data are analyzed. Similarly, because of the number of models used, it is very difficult to compare results from different studies. As the experimental approach is so important to the outcomes, it is an area ripe for consolidation and standardization. Our approach has been to investigate several different models in order to fully explore the complexity of the outcomes under different conditions.

Primary allergen challenge model

Mice do not spontaneously develop AHR or allergic airway inflammation. Therefore, to investigate the development of lung inflammatory responses, an artificial asthma-like reaction has to be induced in the airways. Primary allergen challenge models have been widely used to elucidate the mechanisms underlying the allergen-induced immunologic and inflammatory responses in the airways. Although many different sensitization and challenge protocols exist, the basic model is shared, with a sensitization phase and a challenge phase. Single or multiple systemic injections of allergen with or without adjuvant are used to induce sensitization. Adjuvants such as aluminum hydroxide are known to promote the development of Th2-type responses. Adjuvant-free protocols are also effective, but these usually require a greater number of exposures to achieve the proper sensitization, and even then, elicit less robust responses on allergen challenge.44 In the challenge phase, generally 2-4 weeks after completion of sensitization, allergens are administered in a nebulized form or administered by deposition through the intratracheal or intranasal route. The primary allergen challenge models are relatively short-term and show high reproducibility. The responses elicited include elevated levels of allergen-specific IgE, eosinophilic airway inflammation, and AHR. However, due to the short-term nature of primary allergen challenge models, one of the key features observed in asthmatics, airway remodeling, is minimal and many of the other parameters (AHR, eosinophilic inflammation) are transient. Airway inflammation and AHR have been shown to resolve within a few weeks after the final allergen inhalation.45 It is this model which has been most used in pre-clinical studies, as a prelude to a clinical trial. This model has several limitations and results are often overinterpreted to represent asthma. As a
result, it is not surprising that most extensions to asthma have failed in the clinic. This model is not a model of asthma, the human disease.

**Secondary allergen challenge models**

The responses to primary allergen challenges, including AHR, eosinophilic inflammation, and goblet cell metaplasia can be induced by the first exposures to allergen in sensitized mice. Often described as an acute exposure model, this contrasts with asthma where allergen exposure is repeated and chronic. Therefore, secondary allergen challenge models were developed to more closely mimic the conditions of allergic asthma with allergen re-challenge after animals received sensitization and primary allergen challenge. Animals are exposed to secondary allergen challenge 2-6 weeks after primary allergen challenge when airway eosinophilia and AHR have resolved and returned to baseline levels. A single provocative or secondary allergen challenge elicits airway eosinophilia and neutrophilia, lymphocyte accumulation, and altered airway function. The advantage of this protocol is the ability to monitor the kinetics of inflammatory parameters induced by a single allergen challenge and the effect of treatment. This approach revealed that the requirements for some of the responses to secondary challenge differed from those suggested to be critical in the response to primary allergen challenge.46,47

**Chronic allergen challenge models**

Asthma is defined as a chronic inflammatory disorder of the airways with structural changes in the airways including subepithelial fibrosis, goblet cell metaplasia, smooth muscle thickening, and increased vascularity.46,47 Although primary and secondary allergen challenge animal models elucidate many aspects of human asthma, there are limitations to these models when compared to asthmatics. Several laboratories have investigated chronic allergen challenge models in mice to more closely mimic the human disease. Various models have been developed by increasing the number of allergen exposures over many weeks. OVA as well as other allergens such as HDM elicited chronic allergen challenge models. Animals were exposed to allergen exclusively for 10 days or following passive sensitization with allergen-specific IgE followed by two days of airway allergen challenge. In both cases there was no systemic sensitization. This is similar to the natural mode of sensitization to airborne allergens in asthmatics. Since no adjuvants are used, IgE production and airway inflammatory responses are somewhat lower than observed following systemic sensitization. Importantly, these models, unlike those incorporating systemic sensitization, are both IgE and mast cell-dependent.48

**Dendritic cell-dependent models**

In mice, the sensitization phase can be bypassed using adoptive transfer of allergen-primed dendritic cells (DCs) which are efficient antigen-presenting cells (APC). Bone marrow-derived DCs (BMDCs) can be differentiated and expanded from precursors in vitro in the presence of GM-CSF (with or without IL-4). The bone marrow-derived DCs are primed to allergen and initiate naive T-cell differentiation in vivo when they are adoptively transferred into mice that are then exposed to allergen via the airways on three consecutive days. When allergen-primed DCs are administered directly into the airways of mice followed by exposure to allergen, an asthma-like phenotype is induced. Such experiments have highlighted the importance of DCs in the initiation of allergic airway disease and identify DCs as therapeutic targets. BMDCs are different than the naturally occurring lung DCs, the myeloid and plasmacytoid subsets, that differentially regulate lung allergic responses.46

**MONITORING OUTCOMES IN DIFFERENT MODELS**

The physiologic hallmark of asthma is reversible airway obstruction, accompanied by airway hyperreactivity to bronchoconstrictors and non-specific stimuli. In humans, allergen challenge can induce immediate- and/or late-phase responses. Although assessments of early allergic responses are feasible in mouse models,47 most studies assess changes in airway responsiveness to non-specific agonists such as methacholine (inhaled or administered intravenously) or acetylcholine (administered intravenously) after allergen challenge(s). Allergen...
exposure in sensitized mice results in significant increases in airway responsiveness to cholinergic agonists when compared to the non-exposed controls. Several different methods are used to measure airway responsiveness in mice following allergen exposure (Table 2).

**Non-invasive airway function measurements**

Non-invasive approaches have been used to assess airway function. Spontaneously breathing, non-anesthetized mice are placed in the main chamber of a whole body plethysmograph. The response of the airways to inhaled methacholine is measured and compared to the response to a control inhalant (aerosolized saline). Airway function is expressed as the calculated parameter “enhanced pause” (Penh). Briefly, Penh is an empirical parameter that reflects changes in the box flow waveform between inspiration and expiration and combines these results with the early and late expiratory box flow (Pause). Non-invasive measurements such as this have several potential advantages compared to invasive methods as they are technically less demanding and can be used to monitor AHR over time in the same animal. When carried out in experienced hands, the results correlate with those of the invasive methods. Although faster and somewhat easier, this approach requires careful calibration, may be better suited to responsive strains such as BALB/c mice, and the results can be affected by any impingement on nasal airflow. The validity of this method has been questioned and in fact has engendered a great deal of debate because it is difficult to exclude the influence of the upper airways, and Penh is based on breathing patterns but not physiological values. Investigators have used this technique for screening large numbers of compounds and defining genetic control of airway responsiveness, often in concert with invasive methods to confirm the results.

**Invasive airway function measurements**

Invasive methods more directly measure pulmonary mechanics in mice and represent the current gold standard in airway physiology. AHR can be assessed more directly by measuring changes in respiratory (lung) resistance (Rs) and dynamic compliance (Cdyn) in response to increasing concentrations of inhaled or intravenously administered methacholine or acetylcholine. Rs is the sum of airway and tissue resistance, which is fairly comparable at normal breathing rates. Cdyn is calculated by relating the volume changes to the concomitant elastic recoil pressure changes between end inspiration and end expiration. The advantages of the invasive measurements are the precise assessments of transient changes in pulmonary mechanics. The insertion of a tracheal tube avoids changes secondary to the upper airways and provides the opportunity for extracting bronchoalveolar lavage fluid after lung function measurements are performed. The disadvantages include the need for surgical tracheostomy, thus precluding repeated measurements, the needs for anesthesia, mechanical ventilation, and expertise in handling.

**Electrical field stimulation (EFS)**

Although the in vivo response to inhaled methacholine is the most widely used method of assessing AHR in mice, it was initially limited in the mouse due to the difficulty of delivering an aerosol to the airways. To determine the effects of EFS, tracheal smooth muscle segments (TSM) are isolated after allergen challenge and placed in baths with supporting longitudinally stainless steel wire. Repetitive currents are applied at increasing frequencies to define the frequency that elicits a 50% maximal contraction (ES50). Following allergen challenge, the reduction in ES50 was shown to reflect M2 receptor dysfunction and the increase in acetylcholine release. These alterations may be induced by eosinophilic major basic protein. EFS has been used to investigate mast cell-dependent increases in airway responsiveness and neural airway control.

**SUMMARY**

For the last several decades, various animal models have been studied and have contributed to the further understanding of the mechanisms underlying allergic airway disease. There are very few pathologic features not shared in mouse models and human asthma. The advances in technology, availability of new equipment, introduction of potent reagents and genetically-manipulated mice continue to provide unique opportunities to explore the pathogenesis of allergen-induced airway inflammation and airway dysfunction in ways not available to clinical research in patients. What is lacking is development of guidelines to establish more uniformity in approach and outcomes so that different studies are more easily compared.

Nonetheless, the mouse like other species has several limitations including the facts that they do not have spontaneous symptoms or long-lasting bronchoconstriction as seen in asthmatics, their lungs are more fully developed at birth so environmental influences have different effects, the structure of mouse lungs is very different than in humans, mice are obligate nasal breathers, and chronic asthma models and evidence for remodeling, e.g., smooth muscle hypertrophy is limited. Although no mouse model fully mimics the full range of clinical manifestations of asthma, many do reproduce a collection of the features that characterize its most common forms and they yield a basic core of phenotypic consequences.

In summary, mouse models cannot be considered a surrogate for human asthma or a panacea for difficulties encountered in human study design and outcomes, but rather should be seen as an important opportunity to generate and test hypotheses in simple, controlled systems. The clinical relevance of the findings in mice or any other species can only be determined in human studies.
REFERENCES

1. Asher MI, Montefort S, Bjorksten B, Lai CK, Strachan DP, Weiland SK, Williams H; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006; 368:733-43.

2. Janson C, Anto J, Burney P, Chinn S, de Marco R, Heinrich J, Jarvis D, Kuenzli N, Leynaert B, Luczynska C, Neukirch F, Svanes C, Sunyer J, Wijst M; European Community Respiratory Health Survey II. The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J 2001;18:598-611.

3. Alvarez J, Surs W, Leung DY, Ikle D, Gelfand EW, Szefler SJ. Steroid-resistant asthma: immunologic and pharmacologic features. J Allergy Clin Immunol 1992;89:714-21.

4. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med 2001;344:350-62.

5. Woodcock A, Lowe LA, Murray CS, Pipim SD, Kissen M, Klos A, Kohl J. Cutting edge: guinea pigs with a natural lung inflammation in a brown Norway rat model. Am J Respir Cell Mol Biol 1997;17:702-12.

6. Illi S, von Mutius E, Lau S, Niggemann B, Gruber C, Wahn U; Multicentre Allergy Study (MAS) group. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 2006;368:763-70.

7. Stein RT, Sherrill D, Holberg CJ, Halonen M, Taussig LM, Wright AL, Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999;354:541-5.

8. Venables KM, Chan-Yeung M. Occupational asthma. Lancet 1997;349:1465-9.

9. Trasande L, Thurston GD. The role of air pollution in asthma and other pediatric morbidities. J Allergy Clin Immunol 2005;115:689-99.

10. Stoddard JJ, Miller T. Impact of parental smoking on the prevalence of wheezing respiratory illness in children. Am J Epidemiol 1995; 141:96-102.

11. Bice DE, Seagrace J, Green FH. Animal models of asthma: potential usefulness for studying health effects of inhaled particles. Inhal Toxicol 2000;12:829-62.

12. Karol MH. Animal models of occupational asthma. Eur Respir J 1994;7:555-68.

13. Persson CG, Erjefalt JS, Korsgren M, Sundler F. The mouse trap. Trends Pharmacol Sci 1997;18:465-7.

14. Kips JC, Anderson GP, Fredberg JJ, Herz U, Inman MD, Jordana M, Kemeny DM, Lotvall J, Pauwels RA, Plopper CG, Schmidt D, Sterk PJ, Van Oosterhout AJ, Vargaftig BB, Chung FK. Murine models of asthma. Eur Respir J 2003;22:374-82.

15. Schneider T, van Velzen D, Moqbel R, Issekutz AC. Kinetics and quantitation of eosinophil and neutrophil recruitment to allergic lung inflammation in a brown Norwegian rat model. Am J Respir Cell Mol Biol 1997;17:702-12.

16. Bautsch W, Hoymann HG, Zhang Q, Meier-Wiedenbach I, Raszke U, Ames RS, Sohns B, Flemme N, Meyer zu Vilseck K, Grove M, Klos A, Kohl J. Cutting edge: guinea pigs with a natural C3a-receptor defect exhibit decreased bronchoconstriction in al-lergic airway disease: evidence for an involvement of the C3a anaphylatoxin in the pathogenesis of asthma. J Immunol 2000;165: 5401-5.

17. Colasurdo GN, Hemming VG, Prince GA, Gelfand AS, Loader JE, Larsen GL. Human respiratory syncytial virus produces prolonged alterations of neural control in airways of developing ferrets. Am J Respir Crit Care Med 1999;157:1506-11.

18. Evans MJ, Fanucchi MV, Baker GL, Van Winkle LS, Pantle LM, Nishio SJ, Schelegle ES, Gershwin LJ, Miller LA, Hyde DM, Sannes PL, Plopper CG. Atypical development of the tracheal basement membrane zone of infant rhesus monkeys exposed to ozone and allergen. Am J Physiol Lung Cell Mol Physiol 2003;285:1391-9.

19. Fairbairn SM, Page CP, Lees P, Cunningham FM. Early neutrophil but not eosinophil or platelet recruitment to the lungs of allergic horses following antigen exposure. Clin Exp Allergy 1993;23:821-8.

20. Noelpp B, Noelpp-Eschenhagen I. Experimental bronchial asthma in the guinea pig. IV. Experimental asthma in the guinea pig as an experimental model. Int Arch Allergy Appl Immunol 1952;3:207-17.

21. Ricciardolo FL, Nijkamp F, De Rose V, Folkerks G. The guinea pig as an animal model for asthma. Curr Drug Targets 2008;9:452-65.

22. Watanabe A, Hayashi H. Allergen-induced biphasic bronchoconstriction in rats. Int Arch Allergy Immunol 1990;93:26-34.

23. Bellofiore S, Martin JG. Antigen challenge of sensitized rats increases airway responsiveness to methacholine. J Appl Physiol 1998;85:1642-6.

24. Eidelman DH, Bellofiore S, Martin JG. Late airway responses to antigen challenge in sensitized inbred rats. Am Rev Respir Dis 1988; 137:1033-7.

25. Lowell FC. Observations on Heaves. An Asthma-Like Syndrome in the Horse. J Allergy Clin Immunol 1964;35:322-30.

26. Michoud MC, Pare PD, Boucher R, Hogg JC. Airway responses to histamine and methacholine in Ascaris suum-allergic rhesus monkeys. J Appl Physiol 1978;45:846-51.

27. Ewart SL, Kuperman D, Schadt E, Tankersley C, Grupe A, Shubitowski DM, Peltz G, Wills-Karp M. Quantitative trait loci controlling allergen-induced airway hyperresponsiveness in inbred mice. Am J Respir Cell Mol Biol 2000;23:537-45.

28. McIntyre JJ, Umetsu SE, Akbari O, Potter M, Kuchroo VK, Barsh GS, Freeman GJ, Umetsu DT, DeKruyff RH. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001;2:1109-16.

29. Morokata T, Ishikawa J, Ida K, Yamada T. C57BL/6 mice are more susceptible to antigen-induced pulmonary eosinophilia than BALB/c mice, irrespective of systemic T helper 1/T helper 2 responses. Immunology 1999;98:345-51.

30. Takeda K, Hamelmann E, Joetham A, Shultz LD, Larsen GL, Irvin CG, Gelfand EW. Development of eosinophilic airway inflammation and airway hyperresponsiveness in mast cell-deficient mice. J Exp Med 1997;186:449-54.

31. Fuchs B, Braun A. Improved mouse models of allergy and allergic asthma - chances beyond ovalbumin. Curr Drug Targets 2008;9: 495-502.

32. Conrad ML, Yildirim AO, Sonar SS, Kilic A, Sudohe S, Lunow M, Teich R, Renz H, Garn H. Comparison of adjuvant and adjuvant-free murine experimental asthma models. Clin Exp Allergy 2009; 39:1246-54.

33. Eisenbarth SC, Piggott DA, Hulett JW, Visintin I, Herrick CA, Bottomly K. Lipopolysaccharide-enhanced, toll-like receptor 4-de-
dependent T helper cell type 2 responses to inhaled antigen. J Exp Med 2002;196:1645-51.

34. Swirski FK, Sajic D, Robbins CS, Gajewska BU, Jordana M, Stampfli MR. Chronic exposure to innocuous antigen in sensitized mice leads to suppressed airway eosinophilia that is reversed by granulocyte macrophage colony-stimulating factor. J Immunol 2002;169:3499-506.

35. Barrett EG, Rudolph K, Bowen LE, Muggenburg BA, Bice DE. Effect of inhaled ultrafine carbon particles on the allergic airway response in ragweed-sensitized dogs. Inhal Toxicol 2003;15:151-65.

36. Kurup VP, Chel H, Murali PS, Resnick A, Fink JN, Coffman RL. Role of particulate antigens of Aspergillus in murine eosinophilia. Int Arch Allergy Immunol 1997;112:270-8.

37. Chapoval SP, Ilijima K, Marietta EV, Smart MK, Chapoval AI, Andrews AG, David CS. Allergic inflammatory response to short ragweed allergen extract in HLA-DQ transgenic mice lacking CD4 gene. J Immunol 2002;168:890-9.

38. Lambert AL, Winsett DW, Costa DL, Selgrade MK, Gilmour MI. Transfer of allergic airway responses with serum and lymphocytes from rats sensitized to dust mite. Am J Respir Crit Care Med 1998;157:1991-9.

39. Warner RL, Lukacs NW, Shapiro SD, Bhatt IS, Varani J, Johnson KJ. Role of metalloelastase in a model of allergic lung responses induced by cockroach allergen. Am J Pathol 2004;165:2153-20.

40. Blease K, Jakubzick C, Westwick J, Lukacs N, Kunkel SL, Hogaboam CM. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol 2001;166:5219-24.

41. Obiefuna PC, Batra VK, Nadeem A, Borron P, Wilson CN, Mustafa SJ. A novel A1 adenosine receptor antagonist, L-97-1 [3-[[2-(4aminophenyl)-ethyl]-8-benzyl-7-[2-ethyl-(2-hydroxy-ethyl)]amino-ethyl]-1-propyl-3,7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma. J Pharmocol Exp Ther 2003;315:329-36.

42. Goplen N, Karim MZ, Liang Q, Gorska MM, Rozario S, Guo L, Alam R. Combined sensitization of mice to extracts of dust mite, ragweed, and Aspergillus species breaks through tolerance and elicits IgE responses. J Immunol 2002;168:890-9.

43. Seitzer U, Bussler H, Kullmann B, Petersen A, Becker WM, Ahmed JS. Anti-IgG1 monoclonal antibody neutralizes IgG1-mediated lung inflammation. J Allergy Clin Immunol 2007;119:1241-50.

44. Blyth DI, Pedrick MS, Savage TJ, Hessel EM, Fattah D. Lung inflammation, epithelial lesions and increased methacholine responsiveness following chronic exposure to aerosolised allergen. Thorax 1998;53:849-56.

45. Temelkovski J, Hogan SP, Shepherd DP, Foster PS, Kumar RK. An improved murine model of asthma: selective airway inflammation, epithelial lesions and increased methacholine responsiveness. Thorax 2004;59:784-90.

46. Wegmann M. Animal models of chronic experimental asthma—strategies for the identification of novel therapeutic targets. J Occup Med Toxicol 2008;3 Suppl 1:S4.

47. Fernandez-Rodriguez S, Ford WR, Broadley KJ, Kidd EJ. Establishing the phenotype in novel acute and chronic murine models of allergic asthma. Int Immunopharmacol 2008:8:756-63.

48. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vignola AM. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med 2000;161:1720-45.

49. Fish JE, Peters SP. Airway remodeling and persistent airway obstruction in asthma. J Allergy Clin Immunol 1999;104:509-16.

50. Hamelmann E, Tadeda K, Oshiba A, Gelfand EW. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness—a murine model. Allergy 1999;54:297-305.

51. Swirski FK, Gajewska BU, Alvarez D, Ritz SA, Cundall MJ, Cates EC, Coyle AJ, Gutierrez-Ramos JC, Inman MD, Jordana M, Stampfli MR. Inhalation of a harmless antigen (ovalbumin) elicits immune activation but divergent immunoglobulin and cytokine activities in mice. Clin Exp Allergy 2002:32:411-21.

52. Taube C, Miyahara N, Ott V, Swanson B, Takeda K, Loader J, Shultz LD, Tager AM, Luster AD, Dakahama A, Gelfand EW. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006;176:3157-64.

53. Koya T, Kodama T, Takeda K, Miyahara N, Yang ES, Taube C, Joetham A, Park JW, Dakahama A, Gelfand EW. Importance of myeloid dendritic cells in persistent airway disease after repeated allergen exposure. Am J Respir Crit Care Med 2006;173:42-55.

54. Shingawaga K, Kojima M. Mouse model of airway remodeling: strain differences. Am J Respir Crit Care Med 2003;168:959-67.

55. Boyce JA, Austen KF. No audible wheezing: nuggets and conundrums from mouse asthma models. J Exp Med 2005;201:1869-73.

56. Larsen GL, Renz H, Loader JE, Bradley KL, Gelfand EW. Airway response to electrical field stimulation in sensitized inbred mice. Passive transfer of increased responsiveness with peribronchial lymph nodes. J Clin Invest 1992;99:747-52.

57. Saloga J, Renz H, Lack G, Bradley KL, Greenstein JL, Larsen G, Gelfand EW. Development and transfer of immediate cutaneous hypersensitivity in mice exposed to aerosolized antigen. J Clin Invest 1993;91:133-40.

58. Hamelmann E, Tadeda K, Oshiba A, Gelfand EW. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness—a murine model. Allergy 1999;54:297-305.

59. Swirski FK, Gajewska BU, Alvarez D, Ritz SA, Cundall MJ, Cates EC, Coyle AJ, Gutierrez-Ramos JC, Inman MD, Jordana M, Stampfli MR. Inhalation of a harmless antigen (ovalbumin) elicits immune activation but divergent immunoglobulin and cytokine activities in mice. Clin Exp Allergy 2002:32:411-21.

60. Taube C, Miyahara N, Ott V, Swanson B, Takeda K, Loader J, Shultz LD, Tager AM, Luster AD, Dakahama A, Gelfand EW. The leukotriene B4 receptor (BLT1) is required for effector CD8+ T cell-mediated, mast cell-dependent airway hyperresponsiveness. J Immunol 2006;176:3157-64.

61. Koya T, Matsuda H, Takeda K, Miyahara N, Balhorn A, Dakahama A, Gelfand EW. IL-10-treated dendritic cells decrease airway hyperresponsiveness and airway inflammation in mice. J Allergy Clin Immunol 2007;119:1241-50.

62. Koya T, Matsuda H, Takeda K, Miyahara N, Balhorn A, Gelfand EW. Differential effects of dendritic cell transfer in airway hyperresponsiveness and inflammation. Am J Respir Crit Care Med 2009;181:271-80.

63. Lambrecht BN, De Veerman M, Coyle AJ, Gutierrez-Ramos JC,
Thielemans K, Pauwels RA. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 2000;106:551-9.

65. de Heer HJ, Hammad H, Kool M, Lambrecht BN. Dendritic cell subsets and immune regulation in the lung. Semin Immunol 2005;17:295-303.

66. Lambrecht BN. Lung dendritic cells: targets for therapy in allergic disease. Curr Mol Med 2008;8:393-400.

67. Gieslewicz G, Tomkinson A, Adler A, Duez C, Schwarze J, Takeda K, Larson KA, Lee JJ, Irvin CG, Gelfand EW. The late, but not early, asthmatic response is dependent on IL-5 and correlates with eosinophil infiltration. J Clin Invest 1999;104:301-8.

68. Hamelmann E, Schwarze J, Takeda K, Oshiba A, Larsen GL, Irvin CG, Gelfand EW. Noninvasive measurement of airway responsiveness in allergic mice using barometric plethysmography. Am J Respir Crit Care Med 1997;156:766-75.

69. Lundblad LK, Irvin CG, Hantos Z, Sly P, Mitzner W, Bates JH. Penh is not a measure of airway resistance! Eur Respir J 2007;30:805.

70. Bates JH, Irvin CG. Measuring lung function in mice: the phenotyping uncertainty principle. J Appl Physiol 2003;94:1297-306.

71. Martin TR, Gerard NP, Galli SJ, Drazen JM. Pulmonary responses to bronchoconstrictor agonists in the mouse. J Appl Physiol 1988;64:2318-23.

72. Larsen GL, Fame TM, Renz H, Loader JE, Graves J, Hill M, Gelfand EW. Increased acetylcholine release in tracheas from allergen-exposed IgE-immune mice. Am J Physiol 1994;266:L263-70.

73. Evans CM, Fryer AD, Jacoby DB, Gleich GJ, Costello RW. Pretreatment with antibody to eosinophil major basic protein prevents hyperresponsiveness by protecting neuronal M2 muscarinic receptors in antigen-challenged guinea pigs. J Clin Invest 1997;100:2254-62.

74. Taube C, Wei X, Swasey CH, Joetham A, Zarini S, Lively T, Takeda K, Loader J, Miyahara N, Kodama T, Shultz LD, Donaldson DD, Hamelmann EH, Dakhama A, Gelfand EW. Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant. J Immunol 2004;172:6398-406.